ISS Paris Meeting to Experience Carestream’s Revolutionary Touch Ultrasound and CBCT Systems

GENEVA, Aug. 31 — Carestream will be exhibiting its latest innovations in medical imaging at the International Skeletal Society’s autumn 2016 meeting, to be held in Paris from September 7 – 9th. Attendees, including radiologists, pathologists and orthopaedic surgeons, will be able to explore the CARESTREAM Touch Prime Ultrasound System and CARESTREAM OnSight 3D Extremity System,* both of which offer significant benefits to these specialists and their patients.

With a powerful processor, intuitive interface and ergonomic all-touch control panel, the Carestream Touch Ultrasound delivers high quality images quickly and cost-effectively. A key feature of the system’s design is its sleek, modern control panel which sonographers can configure to suit their personal working preferences. This increases their efficiency and reduces the time patients are required to undergo examinations.

Carestream’s experts will also be on hand to demonstrate the company’s revolutionary OnSight 3D Extremity System. Capable of capturing pristine 2D and 3D images at the point-of-care, the OnSight 3D Extremity system has a wide-opening door and easy, step-in patient access that allows upper and weight-bearing lower extremity exams not possible with traditional CT. It also has a smaller footprint than conventional systems, meaning it can be installed in more practical locations, including in orthopaedic practices. Patients can therefore be examined easily, with minimal inconvenience and reduced exposure.

According to Helen Titus, Marketing Director for X-ray and Ultrasound Solutions at Carestream Health, ‘We have drawn on more than a hundred years of experience to develop these technologies, which both represent a major step forward in musculo-skeletal imaging. This meeting therefore also provides a great opportunity for industry experts to see first-hand the benefits Carestream’s systems can offer their practices and patients.’

###

*EU customers: Device cannot be marketed or sold until compliant with 93/42/EEC